ProjectTHRIVE – TUMOUR-HOST INTERACTIONS IN LIVER CANCER OF CHILDHOOD AND ADULTS
Basic data
Acronym:
THRIVE
Title:
TUMOUR-HOST INTERACTIONS IN LIVER CANCER OF CHILDHOOD AND ADULTS
Duration:
01/12/2023 to 30/11/2028
Abstract / short description:
Liver cancer is a major health problem with ~1 million cases diagnosed each year (~90,000 cases/year in Europe), and it
is the 3rd cause of cancer-related mortality worldwide. Hepatocellular carcinoma (HCC) in adults, and hepatoblastoma
(HB) in children are considered poorly understood cancers. HCC is a difficult-to-cure cancer (curation rate ~ 30%)
with poor outcome (median survival < 2 years in advanced stages), due to limited understanding of at-risk populations,
resistance to therapies and lack of precision oncology. In HB, outcomes are hampered in one fourth of cases due disease
progression after surgical intervention and adjuvant chemotherapy.
THRIVE aims by to improve the outcome of both paediatric and adult liver cancer patients by understanding atrisk
populations, tumour-host interactions, and by developing biomarkers for current therapies and novel, affordable
treatments to overcome resistance. THRIVE brings together a strong, multidisciplinary team -13 partners, from
8 countries- with complementary expertise to leverage cutting-edge technologies (single-cell RNASeq, spatial
transcriptomics, microbiota analysis, artificial intelligence, mouse models and patient-derived organoids) and sectors
(i.e academia, SMEs, hospitals, patient associations) and 15 patient cohorts (~6,700 samples).
THRIVE expects to: 1) Define molecular features of cancer predisposition and at-risk populations for development of
liver cancer. 2) Develop a complete human liver cancer blueprint of tumour, immune, stromal cells and intra-tumoral
microbiomes. 3) Identify AI-based and molecular markers of response to treatments. 4) Implement a preclinical drug
testing platform for discovery of affordable therapies with high social impact. 5) Maximize the impact in the European
society by integrating SSH disciplines, delivering accessible and re-usable data and tools to support EU initiatives such
as the UNCAN.eu platform, and by influencing policymakers and health professionals.
This action is part of the Cancer Mission cluster of projects on “Understanding (tumour-host interactions)".
is the 3rd cause of cancer-related mortality worldwide. Hepatocellular carcinoma (HCC) in adults, and hepatoblastoma
(HB) in children are considered poorly understood cancers. HCC is a difficult-to-cure cancer (curation rate ~ 30%)
with poor outcome (median survival < 2 years in advanced stages), due to limited understanding of at-risk populations,
resistance to therapies and lack of precision oncology. In HB, outcomes are hampered in one fourth of cases due disease
progression after surgical intervention and adjuvant chemotherapy.
THRIVE aims by to improve the outcome of both paediatric and adult liver cancer patients by understanding atrisk
populations, tumour-host interactions, and by developing biomarkers for current therapies and novel, affordable
treatments to overcome resistance. THRIVE brings together a strong, multidisciplinary team -13 partners, from
8 countries- with complementary expertise to leverage cutting-edge technologies (single-cell RNASeq, spatial
transcriptomics, microbiota analysis, artificial intelligence, mouse models and patient-derived organoids) and sectors
(i.e academia, SMEs, hospitals, patient associations) and 15 patient cohorts (~6,700 samples).
THRIVE expects to: 1) Define molecular features of cancer predisposition and at-risk populations for development of
liver cancer. 2) Develop a complete human liver cancer blueprint of tumour, immune, stromal cells and intra-tumoral
microbiomes. 3) Identify AI-based and molecular markers of response to treatments. 4) Implement a preclinical drug
testing platform for discovery of affordable therapies with high social impact. 5) Maximize the impact in the European
society by integrating SSH disciplines, delivering accessible and re-usable data and tools to support EU initiatives such
as the UNCAN.eu platform, and by influencing policymakers and health professionals.
This action is part of the Cancer Mission cluster of projects on “Understanding (tumour-host interactions)".
Involved staff
Managers
Wilhelm Schickard Institute of Computer Science (WSI)
Department of Informatics, Faculty of Science
Department of Informatics, Faculty of Science
Quantitative Biology Center (QBIC)
Central cross-faculty facilities
Central cross-faculty facilities
Institute for Bioinformatics and Medical Informatics (IBMI)
Interfaculty Institutes
Interfaculty Institutes
Other staff
Interfaculty Institute of Biochemistry (IFIB)
Interfaculty Institutes
Interfaculty Institutes
Department of Systems Neuroscience
Hertie Institute for Clinical Brain Research (HIH), Non-clinical institutes, Faculty of Medicine
Hertie Institute for Clinical Brain Research (HIH), Non-clinical institutes, Faculty of Medicine
Quantitative Biology Center (QBIC)
Central cross-faculty facilities
Central cross-faculty facilities
Local organizational units
Quantitative Biology Center (QBIC)
Central cross-faculty facilities
University of Tübingen
University of Tübingen
Funders
Brüssel, Belgium
Cooperations
Newcastle upon Tyne, United Kingdom
Paris, France
Rechovot, Israel